Phase 0 pharmacodynamic study of poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with refractory solid tumors and lymphomas: Immunohistochemistry results

被引：3
|
作者：
Yang, S. X.
Kummar, S.
Rubinstein, L.
Gutierrez, M.
Murgo, A. J.
Parchment, R. E.
Nguyen, D.
Chen, A. P.
Tomaszewski, J. E.
Doroshow, J. H.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] SAIC Inc, Frederick, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.3580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3580
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas
    Yang, Sherry X.
    Kummar, Shivaani
    Steinberg, Seth M.
    Murgo, Anthony J.
    Gutierrez, Martin
    Rubinstein, Larry
    Nguyen, Dat
    Kaur, Gurmeet
    Chen, Alice P.
    Giranda, Vincent L.
    Tomaszewski, Joseph E.
    Doroshow, James H.
    CANCER BIOLOGY & THERAPY, 2009, 8 (21) : 2004 - 2009
  • [2] Phase 0 pharmacodynamic, pharmacokinetic study of ABT-888, an inhibitor of poly (ADP-ribose) polymerase (PARP), in patients with advanced malignancies
    Kummar, S.
    Gutierrez, M.
    Kinders, R.
    Rubinstein, L.
    Parchment, R. E.
    Phillips, L.
    Ji, J.
    Chen, A.
    Homeffer, Y.
    Juwara, L.
    Yancey, M.
    Murgo, A. J.
    Collins, J. M.
    Tomaszewski, J. E.
    Doroshow, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 20 - 20
  • [3] Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
    Kummar, Shivaani
    Kinders, Robert
    Gutierrez, Martin E.
    Rubinstein, Larry
    Parchment, Ralph E.
    Phillips, Lawrence R.
    Ji, Jiuping
    Monks, Anne
    Low, Jennifer A.
    Chen, Alice
    Murgo, Anthony J.
    Collins, Jerry
    Steinberg, Seth M.
    Eliopoulos, Helen
    Giranda, Vincent L.
    Gordon, Gary
    Helman, Lee
    Wiltrout, Robert
    Tomaszewski, Joseph E.
    Doroshow, James H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2705 - 2711
  • [4] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
    LoRusso, Patricia M.
    Li, Jing
    Burger, Angelika
    Heilbrun, Lance K.
    Sausville, Edward A.
    Boerner, Scott A.
    Smith, Daryn
    Pilat, Mary Jo
    Zhang, Jie
    Tolaney, Sara M.
    Cleary, James M.
    Chen, Alice P.
    Rubinstein, Lawrence
    Boerner, Julie L.
    Bowditch, Adam
    Cai, Dongpo
    Bell, Tracy
    Wolanski, Andrew
    Marrero, Allison M.
    Zhang, Yiping
    Ji, Jiuping
    Ferry-Galow, Katherine
    Kinders, Robert J.
    Parchment, Ralph E.
    Shapiro, Geoffrey I.
    CLINICAL CANCER RESEARCH, 2016, 22 (13) : 3227 - 3237
  • [5] ABT-888: A potent and orally efficacious inhibitor of poly(ADP-ribose)polymerase
    Penning, Thomas D.
    Zhu, Gui-Dong
    Gandhi, Viraj B.
    Gong, Jianchun
    Liu, Xuesong
    Shi, Yan
    Klinghofer, Vered
    Johnson, Eric F.
    Donawho, Cherrie K.
    Frost, David J.
    Bontecheva-Diaz, Velkitchka
    Bouska, Jennifer J.
    Osterling, Donald J.
    Olson, Amanda M.
    Marsh, Kerman C.
    Luo, Yan
    Giranda, Vincent L.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [6] Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: Results of a phase 0 trial
    Kummar, S.
    Kinders, R.
    Gutierrez, M.
    Rubinstein, L.
    Parchment, R. E.
    Phillips, L. R.
    Low, J.
    Murgo, A. J.
    Tomaszewski, J. E.
    Doroshow, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
    Leonard J. Appleman
    Jan H. Beumer
    Yixing Jiang
    Yan Lin
    Fei Ding
    Shannon Puhalla
    Leigh Swartz
    Taofeek K. Owonikoko
    R. Donald Harvey
    Ronald Stoller
    Daniel P. Petro
    Hussein A. Tawbi
    Athanassios Argiris
    Sandra Strychor
    Marie Pouquet
    Brian Kiesel
    Alice P. Chen
    David Gandara
    Chandra P. Belani
    Edward Chu
    Suresh S. Ramalingam
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 1289 - 1301
  • [8] Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
    Appleman, Leonard J.
    Beumer, Jan H.
    Jiang, Yixing
    Lin, Yan
    Ding, Fei
    Puhalla, Shannon
    Swartz, Leigh
    Owonikoko, Taofeek K.
    Harvey, R. Donald
    Stoller, Ronald
    Petro, Daniel P.
    Tawbi, Hussein A.
    Argiris, Athanassios
    Strychor, Sandra
    Pouquet, Marie
    Kiesel, Brian
    Chen, Alice P.
    Gandara, David
    Belani, Chandra P.
    Chu, Edward
    Ramalingam, Suresh S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (06) : 1289 - 1301
  • [9] Recruitment experience in a phase 0 trial of ABT-888, an inhibitor of poly (ADP-ribose) polymerase (PARP), in patients (pts) with advanced malignancies
    Gutierrez, M.
    Kummar, S.
    Horneffer, Y.
    Juwara, L.
    Chen, A.
    Melillo, G.
    Pickeral, O.
    Tomaszewski, J. E.
    Murgo, A. J.
    Doroshow, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma
    Barazzuol, Lara
    Jena, Raj
    Burnet, Neil G.
    Meira, Lisiane B.
    Jeynes, Jonathan C. G.
    Kirkby, Karen J.
    Kirkby, Norman F.
    RADIATION ONCOLOGY, 2013, 8
12345